IP Library Granted Patent US 8,691,549
Granted Patent B2
US 8,691,549 · App. 13/736,296 · Granted Apr 8, 2014

High fidelity restriction endonucleases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,691,549
App. No.
13/736,296
Granted
Apr 8, 2014
Kind
B2
Abstract

Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.

Claims (8)

1. A composition comprising a variant SalI restriction endonuclease having reduced star activity, wherein the variant SalI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent SalI restriction endonuclease by a mutation at an amino acid position corresponding to position 82 in SEQ ID NO:94.

2. A composition according to claim 1 , wherein the mutation is R82A.

3. A composition comprising a variant SalI restriction endonuclease having reduced star activity, wherein the variant SalI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent SalI restriction endonuclease by a mutation at an amino acid position corresponding to position 93 in SEQ ID NO:94.

4. A composition according to claim 3 , wherein the mutation is K93A.

5. A composition comprising a variant SalI restriction endonuclease having reduced star activity, wherein the variant SalI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent SalI restriction endonuclease by a mutation at an amino acid position corresponding to position 101 in SEQ ID NO:94.

6. A composition according to claim 5 , wherein the mutation is K101A.

7. A composition comprising a variant SalI restriction endonuclease having reduced star activity, wherein the variant SalI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent SalI restriction endonuclease by a mutation at an amino acid position corresponding to position 107 in SEQ ID NO:94.

8. A composition according to claim 7 , wherein the mutation is R107A.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2023
From: ZHU, ZHENYU; QUIMBY, AINE; XU, SHUANG-YONG; GUAN, SHENGXI; WEI, HUA; ZHANG, PENGHUA; SUN, DAPENG; CHAN, SIU-HONG
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 064574/0948 →